• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IXC 0.00% 7.6¢

INVEX THERAPEUTICS LTD - Announcements

Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is... Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. It has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The Company is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

Filters [Clear]
  • Price Sensitive: Yes

No announcements returned.

(20min delay)
Last
7.6¢
Change
0.000(0.00%)
Mkt cap ! $5.636M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 62461 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 5490 1
View Market Depth
Last trade - 16.12pm 22/11/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.